ClinicalTrials.gg
CompletedNCT04829318ESCAPE-LTEUpdated Sep 18, 2025Results posted

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

A Phase 4 interventional study of Esketamine and SSRI/SNRI in Depressive Disorder, Major, sponsored by Janssen-Cilag Ltd.. Completed at 59 sites in 14 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Janssen-Cilag Ltd. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
183
Allocation
Not applicable
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing esketamine in Depressive Disorder, Major — 5 open to participants now, 5 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Major.

Enrollment
6th of 17
183 · median 147
Started
2021
with 1 other
Phase 4
4 of 17
2 open now
Registered
10th of 17
by date
Lead sponsor
1 of 17
Janssen-Cilag Ltd.

Among the 17 studies testing esketamine in Depressive Disorder, Major, this one is the 6th largest by enrollment, is one of 2 that started in 2021, is one of 4 in phase 4, and was the 10th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

5 of the 17 studies testing esketamine in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About esketamine

Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing esketamine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The primary purpose of this study is to assess the long-term safety and tolerability of esketamine nasal spray in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) in participants who have completed 32 weeks of esketamine nasal spray treatment in Study 54135419TRD3013 (NCT04338321).

03

Conditions studied

  • Depressive Disorder, Major

Keywords

  • Treatment resistant depression
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed the maintenance phase (Week 32) of Study 54135419TRD3013 (NCT04338321) and had esketamine nasal spray in combination with continuing selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) administered through Week 30 (every 2 week dosing) or Week 31 (once weekly dosing) of Study 54135419TRD3013, and continues to be willing to be treated with esketamine nasal spray
  • Must, in the opinion of the investigator, be benefiting from continuation of esketamine nasal spray in combination with their current SSRI/SNRI based on efficacy and tolerability assessed on Day 1 of this study
  • Must be medically stable based on the investigator's judgment
  • A woman of must have a negative urine pregnancy test on Day 1
  • Male participants who are sexually active with a woman of childbearing potential must agree to the following during the intervention period and for at least 1 spermatogenesis cycle (defined as approximately 90 days) after receiving the last dose of study intervention (that is, esketamine nasal spray), must fulfill the following criteria: must be practicing a highly effective method of with his female partner, must use a condom if his partner is pregnant, and must agree not to donate sperm

Exclusion criteria

Exclusion Criteria:

  • Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
  • Completed Study 54135419TRD3013 while presenting adverse events deemed by the investigator, and which may interfere with safety and well-being of the participant
  • Has developed during participation in Study 54135419TRD3013 any of the following cardiovascular-related conditions where an increase in blood pressure or intracranial pressure poses a serious risk: cerebrovascular disease following stroke or , aneurysmal vascular disease (including intracranial, thoracic, or abdominal aorta, or peripheral arterial vessels), intracerebral hemorrhage, coronary artery disease following myocardial infarction, unstable angina, or revascularization procedure (example, coronary angioplasty or bypass graft surgery), uncontrolled brady- or tachyarrhythmias that lead to hemodynamic instability, hemodynamically significant valvular heart disease such as mitral regurgitation, aortic stenosis, or aortic regurgitation or heart failure ( [NYHA] Class III-IV) of any etiology
  • Significant pulmonary insufficiency, including
  • Has homicidal ideation or intent, per the investigator's clinical judgment; or has suicidal ideation with some intent to act within 1 month prior to Day 1, per the investigator's clinical judgment; or based on the Columbia-suicide severity rating scale (C-SSRS) performed at Week 32 visit of Study 54135419TRD3013, corresponding to a response of "Yes" on Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) for suicidal ideation
  • Pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 90 days after the last dose of study intervention
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
183 participants (actual)

Study arms

  • Experimental
    Esketamine

    Participants who were randomly assigned to the esketamine arm in Study 54135419TRD3013 (NCT04338321), had esketamine nasal spray administered through Week 30 (every 2 weeks dosing) or Week 31 (once weekly dosing), completed the maintenance phase at Week 32 will continue to receive esketamine nasal spray once weekly or every 2 weeks along with serotonin-norepinephrine reuptake inhibitor/selective serotonin reuptake inhibitor (SSRI/SNRI) in this long-term extension (LTE) study. The duration of the study participation is 2 years or when esketamine is commercially available.

    Drug: Esketamine · Drug: SSRI/SNRI

Interventions

  • Esketamine will be self-administered as nasal spray.

  • DrugSSRI/SNRI

    Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the summary of product characteristics (SmPC) (or local equivalent, if applicable). During this LTE study, investigators will be allowed to switch individual participant's SSRI/SNRI for tolerability issues.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    Percentage of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious adverse events.

    Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)

  2. Incidence Rate of Treatment-emergent Adverse Events (TEAEs)

    Incidence rate of TEAEs were reported. AE Incidence rate was defined as incidence rate per 100 patient-months = (number of participants with AE divided by sum of days at risk for AE) \* 100\*365.25/12. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious adverse events.

    Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)

  3. Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs)

    Percentage of participants with TESAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent.

    Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)

  4. Incidence Rate of Treatment-emergent Serious Adverse Events (TESAEs)

    Incidence rate of with TESAEs were reported. AE Incidence rate was defined as incidence rate per 100 patient-months = (number of participants with AE divided by sum of days at risk for AE) \* 100\*365.25/12. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent.

    Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)

  5. Percentage of of Participants With TEAEs Leading to Death

    Percentage of participants with TEAEs leading to death were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious adverse events.

    Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)

  6. Incidence Rate of TEAEs Leading to Death

    Incidence rate of TEAEs leading to death were reported. AE Incidence rate was defined as incidence rate per 100 patient-months = (number of participants with AE divided by sum of days at risk for AE) \* 100\*365.25/12. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious adverse events.

    Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)

  7. Percentage of Participants With Treatment-emergent AEs of Special Interest (AESIs)

    Percentage of participants with TEAEs of special interest were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious AEs. AEs of special interest were separately grouped by categories sedation, dissociation, suicidality, suggestive of abuse potential, cystitis and hepatic impairment.

    Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)

  8. Incidence Rate of Treatment-emergent AEs of Special Interest (AESIs)

    AE Incidence rate: incidence rate per 100 patient-months=(number of participants with AE divided by sum of days at risk for AE)\* 100\*365.25/12. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with intervention. SAE: AE resulting in any following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial intervention administration up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious AEs. AEs of special interest were grouped as categories sedation, dissociation, suicidality, suggestive of abuse potential, cystitis and hepatic impairment.

    Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)

  9. Number of Participants With Suicidal Ideation and Behavior in Study 54135419TRD4010 as Assessed by Columbia-suicide Severity Rating Scale (C-SSRS) Score

    Number of participants with suicidal ideation and behavior in study 54135419TRD4010 as assessed by C-SSRS score were reported. C-SSRS score: an assessment tool that evaluated suicidal ideation and behavior. Suicidal ideation (5 items): wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, and active suicidal ideation with specific plan and intent. Suicidal behavior (5 items): preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt (non-fatal), and suicide. Total score from 10 categories was summarized into 3 categories: No suicidal ideation or behavior (0), Suicidal ideation (1 to 5), Suicidal behavior (6 to 10). Total score ranged from 0 to 10. Higher scores indicated more severe suicidal ideation and behavior.

    Time frame: Baseline (Day 1 of Study 54135419TRD3013) up to Week 104 of study 54135419TRD4010 (up to Week 136)

Secondary outcomes

  1. Percentage of Participants With No Relapse and Without Discontinuation Until the End of the Prospective Observation Period at Week 104

    Relapse was defined by any of the following: a) Worsening of depressive symptoms as indicated by Montgomery-Asberg Depression Rating Scale (MADRS) total score \>=22 confirmed by 1 additional assessment of MADRS total score \>=22 within the next 5 to 31 days. b) Any psychiatric hospitalization for: 1) worsening of depression, 2) suicide prevention or due to a suicide attempt for any of these events. c) Suicide attempt, completed suicide, or any other clinically relevant event determined per investigator's clinical judgment to be indicative of relapse of depressive illness, but for which participant was not hospitalized. MADRS scale consisted of 10 items, scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 0 to 60. Higher scores represented a more severe condition.

    Time frame: Baseline (Day 1 of Study 54135419TRD3013) up to Week 104 of study 54135419TRD4010 (up to Week 136)

  2. Change From Baseline of Study 54135419TRD3013 in Clinician-rated Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    Change from baseline of study 54135419TRD3013 in Clinician-rated MADRS total score were reported. MADRS was a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items , scored from 0 (item is not present or normal) to 6 (severe or continuous presence of symptoms), summed up for a total possible score range of 0 to 60. Higher scores represented a more severe condition. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts.

    Time frame: Baseline (Day 1 of study 54135419TRD3013) up to weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, and 104 of study 54135419TRD4010

  3. Change From Baseline of Study 54135419TRD3013 in Clinician-rated Montgomery-Asberg Depression Rating Scale (MADRS) Score Individual Items

    Change from Baseline of Study 54135419TRD3013 in Clinician-rated MADRS Score Individual Items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts) were reported. MADRS was a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), summed up for a total possible score range of 0 to 60. Higher scores represent a more severe condition.

    Time frame: Baseline (Day 1 of study 54135419TRD3013) up to weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, and 104 of study 54135419TRD4010

  4. Change From Baseline of Study 54135419TRD3013 in Clinical Global Impression -Severity (CGI-S) Scale Score

    Change from Baseline of Study 54135419TRD3013 in CGI-S scale score were reported. The CGI-S provided an overall clinician-determined summary measure of the severity of the participant's illness that took into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluated the severity of psychopathology on a scale of 1 to 7: where, 1 = normal (not ill); 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participant's. Negative change in score indicated improvement. Participant's with a score of zero were considered missing.

    Time frame: Baseline (Day 1 of study 54135419TRD3013) up to weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, and 104 of study 54135419TRD4010

  5. Change From Baseline of Study 54135419TRD3013 in Patient Health Questionnaire (PHQ) 9-item Total Score

    Change from Baseline of Study 54135419TRD3013 in PHQ 9-item total score were reported. The PHQ-9 was a validated 9-item, patient-reported outcome (PRO) measure to assess depressive symptoms. Each item was rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses were summed to a total score with a range of 0 to 27. Higher scores indicated greater severity of depressive symptoms.

    Time frame: Baseline (Day 1 of study 54135419TRD3013) up to weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, and 104 of study 54135419TRD4010

  6. Change From Baseline of Study 54135419TRD3013 in European Quality of Life (EuroQol) 5 Dimension 5-Level (EQ-5D-5L): Health Status Index

    Change from baseline of Study 54135419TRD3013 in EQ-5D-5LQuestionnaire Score: health status index were reported. The EQ-5D-5L descriptive system comprised the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions were divided into 5 levels of perceived problems (level 1 = no problem, level 2 = slight problems, level 3 = moderate problems, level 4 = severe problems, level 5 = extreme problems). The participant selected an answer for each of the 5 dimensions considering a response that best matched participant's health "today." Responses were used to generate health status index ranged from -0.594 to 1 (where 1 represents full health and negative values represent health states considered worse than dead). Positive change in score indicated improvement.

    Time frame: Baseline (Day 1 of Study 54135419TRD3013) up to weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, and 104 of study 54135419TRD4010

  7. Change From Baseline of Study 54135419TRD3013 in European Quality of Life (EuroQol) 5 Dimension 5-Level (EQ-5D-5L): Visual Analogue Scale (VAS)

    Change from baseline of Study 54135419TRD3013 in EQ-5D-5L: visual analogue scale were reported. EQ-VAS self-rating recorded the participant's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Positive change in score indicated improvement.

    Time frame: Baseline (Day 1 of Study 54135419TRD3013) up to weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, and 104 of study 54135419TRD4010

07

Results

Posted Sep 18, 2025

Participant flow

Participant flow — Overall Study
MilestoneEsketamine Nasal Spray + Oral Antidepressant (AD)
Started183
Treated with esketamine 28 mg2
Treated with esketamine 56 mg68
Treated with esketamine 84 mg113
Treated with oral ad182
Completed148
Not completed35
Withdrew: Adverse event6
Withdrew: Death1
Withdrew: Lost to follow-up1
Withdrew: Physician decision1
Withdrew: Withdrawal by subject19
Withdrew: Site terminated by sponsor1
Withdrew: Sponsor decision5
Withdrew: Other1

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

Percentage of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious adverse events.

Time frame:
From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
percentage of participantsEsketamine Nasal Spray + Oral Antidepressant (AD)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)88.0
PrimaryIncidence Rate of Treatment-emergent Adverse Events (TEAEs)

Incidence rate of TEAEs were reported. AE Incidence rate was defined as incidence rate per 100 patient-months = (number of participants with AE divided by sum of days at risk for AE) \* 100\*365.25/12. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious adverse events.

Time frame:
From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
Reported as:
Number · AEs per 100 patient-months
Incidence Rate of Treatment-emergent Adverse Events (TEAEs)
AEs per 100 patient-monthsEsketamine Nasal Spray + Oral Antidepressant (AD)
Incidence Rate of Treatment-emergent Adverse Events (TEAEs)17.33 (14.85 to 20.23)
PrimaryPercentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs)

Percentage of participants with TESAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent.

Time frame:
From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
percentage of participantsEsketamine Nasal Spray + Oral Antidepressant (AD)
Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs)6.0
PrimaryIncidence Rate of Treatment-emergent Serious Adverse Events (TESAEs)

Incidence rate of with TESAEs were reported. AE Incidence rate was defined as incidence rate per 100 patient-months = (number of participants with AE divided by sum of days at risk for AE) \* 100\*365.25/12. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent.

Time frame:
From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
Reported as:
Number · AEs per 100 patient-months
Incidence Rate of Treatment-emergent Serious Adverse Events (TESAEs)
AEs per 100 patient-monthsEsketamine Nasal Spray + Oral Antidepressant (AD)
Incidence Rate of Treatment-emergent Serious Adverse Events (TESAEs)0.28 (0.16 to 0.51)
PrimaryPercentage of of Participants With TEAEs Leading to Death

Percentage of participants with TEAEs leading to death were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious adverse events.

Time frame:
From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
Reported as:
Number · percentage of participants
Percentage of of Participants With TEAEs Leading to Death
percentage of participantsEsketamine Nasal Spray + Oral Antidepressant (AD)
Percentage of of Participants With TEAEs Leading to Death0.6 (0.16 to 0.51)
PrimaryIncidence Rate of TEAEs Leading to Death

Incidence rate of TEAEs leading to death were reported. AE Incidence rate was defined as incidence rate per 100 patient-months = (number of participants with AE divided by sum of days at risk for AE) \* 100\*365.25/12. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious adverse events.

Time frame:
From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
Reported as:
Number · AEs per 100 patient-months
Incidence Rate of TEAEs Leading to Death
AEs per 100 patient-monthsEsketamine Nasal Spray + Oral Antidepressant (AD)
Incidence Rate of TEAEs Leading to Death0.03 (0.00 to 0.18)
PrimaryPercentage of Participants With Treatment-emergent AEs of Special Interest (AESIs)

Percentage of participants with TEAEs of special interest were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious AEs. AEs of special interest were separately grouped by categories sedation, dissociation, suicidality, suggestive of abuse potential, cystitis and hepatic impairment.

Time frame:
From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent AEs of Special Interest (AESIs)
percentage of participantsEsketamine Nasal Spray + Oral Antidepressant (AD)
Sedation16.9
Dissociation12.0
Suicidality3.8
Suggestive of abuse potential37.7
Cystitis0.5
PrimaryIncidence Rate of Treatment-emergent AEs of Special Interest (AESIs)

AE Incidence rate: incidence rate per 100 patient-months=(number of participants with AE divided by sum of days at risk for AE)\* 100\*365.25/12. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with intervention. SAE: AE resulting in any following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial intervention administration up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious AEs. AEs of special interest were grouped as categories sedation, dissociation, suicidality, suggestive of abuse potential, cystitis and hepatic impairment.

Time frame:
From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
Reported as:
Number · AEs per 100 patient-months
Incidence Rate of Treatment-emergent AEs of Special Interest (AESIs)
AEs per 100 patient-monthsEsketamine Nasal Spray + Oral Antidepressant (AD)
Sedation0.91
Dissociation0.61
Suicidality0.18
Suggestive of abuse potential2.63
Cystitis0.03
PrimaryNumber of Participants With Suicidal Ideation and Behavior in Study 54135419TRD4010 as Assessed by Columbia-suicide Severity Rating Scale (C-SSRS) Score

Number of participants with suicidal ideation and behavior in study 54135419TRD4010 as assessed by C-SSRS score were reported. C-SSRS score: an assessment tool that evaluated suicidal ideation and behavior. Suicidal ideation (5 items): wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, and active suicidal ideation with specific plan and intent. Suicidal behavior (5 items): preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt (non-fatal), and suicide. Total score from 10 categories was summarized into 3 categories: No suicidal ideation or behavior (0), Suicidal ideation (1 to 5), Suicidal behavior (6 to 10). Total score ranged from 0 to 10. Higher scores indicated more severe suicidal ideation and behavior.

Time frame:
Baseline (Day 1 of Study 54135419TRD3013) up to Week 104 of study 54135419TRD4010 (up to Week 136)
Reported as:
Count of participants · Participants
Number of Participants With Suicidal Ideation and Behavior in Study 54135419TRD4010 as Assessed by Columbia-suicide Severity Rating Scale (C-SSRS) Score
ParticipantsEsketamine Nasal Spray + Oral Antidepressant (AD)
No suicidal ideation or behavior158
Suicidal ideation24
Suicidal behavior1
SecondaryPercentage of Participants With No Relapse and Without Discontinuation Until the End of the Prospective Observation Period at Week 104

Relapse was defined by any of the following: a) Worsening of depressive symptoms as indicated by Montgomery-Asberg Depression Rating Scale (MADRS) total score \>=22 confirmed by 1 additional assessment of MADRS total score \>=22 within the next 5 to 31 days. b) Any psychiatric hospitalization for: 1) worsening of depression, 2) suicide prevention or due to a suicide attempt for any of these events. c) Suicide attempt, completed suicide, or any other clinically relevant event determined per investigator's clinical judgment to be indicative of relapse of depressive illness, but for which participant was not hospitalized. MADRS scale consisted of 10 items, scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 0 to 60. Higher scores represented a more severe condition.

Time frame:
Baseline (Day 1 of Study 54135419TRD3013) up to Week 104 of study 54135419TRD4010 (up to Week 136)
Reported as:
Number · percentage of participants
Percentage of Participants With No Relapse and Without Discontinuation Until the End of the Prospective Observation Period at Week 104
percentage of participantsEsketamine Nasal Spray + Oral Antidepressant (AD)
Percentage of Participants With No Relapse and Without Discontinuation Until the End of the Prospective Observation Period at Week 10479.2
SecondaryChange From Baseline of Study 54135419TRD3013 in Clinician-rated Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

Change from baseline of study 54135419TRD3013 in Clinician-rated MADRS total score were reported. MADRS was a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items , scored from 0 (item is not present or normal) to 6 (severe or continuous presence of symptoms), summed up for a total possible score range of 0 to 60. Higher scores represented a more severe condition. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts.

Time frame:
Baseline (Day 1 of study 54135419TRD3013) up to weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, and 104 of study 54135419TRD4010
Reported as:
Mean · score on a scale
Change From Baseline of Study 54135419TRD3013 in Clinician-rated Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
score on a scaleEsketamine Nasal Spray + Oral Antidepressant (AD)
Week 4-21.9 ± 8.10
Week 8-21.8 ± 7.93
Week 12-22.5 ± 7.25
Week 16-22.8 ± 7.24
Week 20-22.3 ± 7.26
Week 24-22.6 ± 6.82
Week 28-22.4 ± 7.13
Week 32-22.5 ± 7.16
Week 36-22.5 ± 8.12
Week 40-22.7 ± 7.03
Week 44-22.9 ± 7.41
Week 48-22.9 ± 7.19
Week 52-22.6 ± 7.13
Week 56-23.0 ± 6.88
Week 60-23.1 ± 7.11
Week 64-23.4 ± 7.52
Week 68-23.2 ± 7.10
Week 72-23.6 ± 6.98
Week 76-23.8 ± 6.91
Week 80-23.7 ± 7.19
Week 84-23.6 ± 6.87
Week 88-24.4 ± 6.78
Week 92-24.3 ± 7.17
Week 96-24.7 ± 6.57
Week 100-24.9 ± 6.39
Week 104-25.3 ± 6.69
SecondaryChange From Baseline of Study 54135419TRD3013 in Clinician-rated Montgomery-Asberg Depression Rating Scale (MADRS) Score Individual Items

Change from Baseline of Study 54135419TRD3013 in Clinician-rated MADRS Score Individual Items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts) were reported. MADRS was a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), summed up for a total possible score range of 0 to 60. Higher scores represent a more severe condition.

Time frame:
Baseline (Day 1 of study 54135419TRD3013) up to weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, and 104 of study 54135419TRD4010
Reported as:
Mean · score on a scale
Change From Baseline of Study 54135419TRD3013 in Clinician-rated Montgomery-Asberg Depression Rating Scale (MADRS) Score Individual Items
score on a scaleEsketamine Nasal Spray + Oral Antidepressant (AD)
Week 4: Apparent Sadness-3.0 ± 1.38
Week 8: Apparent Sadness-3.0 ± 1.45
Week 12: Apparent Sadness-3.0 ± 1.34
Week 16: Apparent Sadness-3.1 ± 1.34
Week 20: Apparent Sadness-3.1 ± 1.31
Week 24: Apparent Sadness-2.9 ± 1.36
Week 28: Apparent Sadness-3.0 ± 1.33
Week 32: Apparent Sadness-3.0 ± 1.28
Week 36: Apparent Sadness-3.0 ± 1.42
Week 40: Apparent Sadness-3.0 ± 1.36
Week 44: Apparent Sadness-3.1 ± 1.38
Week 48: Apparent Sadness-3.1 ± 1.34
Week 52: Apparent Sadness-3.1 ± 1.32
Week 56: Apparent Sadness-3.1 ± 1.23
Week 60: Apparent Sadness-3.1 ± 1.24
Week 64: Apparent Sadness-3.2 ± 1.33
Week 68: Apparent Sadness-3.1 ± 1.23
Week 72: Apparent Sadness-3.2 ± 1.21
Week 76: Apparent Sadness-3.3 ± 1.22
Week 80: Apparent Sadness-3.3 ± 1.24
Week 84: Apparent Sadness-3.2 ± 1.15
Week 88: Apparent Sadness-3.4 ± 1.17
Week 92: Apparent Sadness-3.3 ± 1.20
Week 96: Apparent Sadness-3.3 ± 1.20
Week 100: Apparent Sadness-3.4 ± 1.13
Week 104: Apparent Sadness-3.5 ± 1.20
Week 4: Reported Sadness-3.1 ± 1.29
Week 8: Reported Sadness-3.0 ± 1.38
Week 12: Reported Sadness-3.0 ± 1.20
Week 16: Reported Sadness-3.1 ± 1.28
Week 20: Reported Sadness-3.1 ± 1.24
Week 24: Reported Sadness-3.1 ± 1.19
Week 28: Reported Sadness-3.0 ± 1.21
Week 32: Reported Sadness-3.1 ± 1.18
Week 36: Reported Sadness-3.0 ± 1.23
Week 40: Reported Sadness-3.2 ± 1.18
Week 44: Reported Sadness-3.1 ± 1.23
Week 48: Reported Sadness-3.1 ± 1.22
Week 52: Reported Sadness-3.1 ± 1.19
Week 56: Reported Sadness-3.2 ± 1.12
Week 60: Reported Sadness-3.3 ± 1.14
Week 64: Reported Sadness-3.3 ± 1.26
Week 68: Reported Sadness-3.2 ± 1.24
Week 72: Reported Sadness-3.2 ± 1.20
Week 76: Reported Sadness-3.3 ± 1.16
Week 80: Reported Sadness-3.3 ± 1.12
Week 84: Reported Sadness-3.3 ± 1.10
Week 88: Reported Sadness-3.3 ± 1.14
Week 92: Reported Sadness-3.3 ± 1.24
Week 96: Reported Sadness-3.4 ± 1.03
Week 100: Reported Sadness-3.4 ± 1.05
Week 104: Reported Sadness-3.5 ± 1.07
Week 4: Inner Tension-1.8 ± 1.19
Week 8: Inner Tension-1.8 ± 1.18
Week 12: Inner Tension-1.9 ± 1.20
Week 16: Inner Tension-1.9 ± 1.15
Week 20: Inner Tension-1.8 ± 1.19
Week 24: Inner Tension-1.9 ± 1.21
Week 28: Inner Tension-1.8 ± 1.23
Week 32: Inner Tension-1.9 ± 1.23
Week 36: Inner Tension-2.0 ± 1.07
Week 40: Inner Tension-1.8 ± 1.17
Week 44: Inner Tension-1.9 ± 1.20
Week 48: Inner Tension-2.0 ± 1.25
Week 52: Inner Tension-1.9 ± 1.16
Week 56: Inner Tension-2.0 ± 1.20
Week 60: Inner Tension-1.9 ± 1.32
Week 64: Inner Tension-2.0 ± 1.34
Week 68: Inner Tension-1.9 ± 1.26
Week 72: Inner Tension-2.0 ± 1.26
Week 76: Inner Tension-2.0 ± 1.22
Week 80: Inner Tension-2.1 ± 1.13
Week 84: Inner Tension-2.0 ± 1.28
Week 88: Inner Tension-2.0 ± 1.20
Week 92: Inner Tension-2.0 ± 1.16
Week 96: Inner Tension-2.0 ± 1.14
Week 100: Inner Tension-2.0 ± 1.18
Week 104: Inner Tension-2.1 ± 1.22
Week 4: Reduced Sleep-2.1 ± 1.72
Week 8: Reduced Sleep-2.2 ± 1.64
Week 12: Reduced Sleep-2.2 ± 1.63
Week 16: Reduced Sleep-2.2 ± 1.75
Week 20: Reduced Sleep-2.3 ± 1.72
Week 24: Reduced Sleep-2.2 ± 1.68
Week 28: Reduced Sleep-2.2 ± 1.72
Week 32: Reduced Sleep-2.3 ± 1.70
Week 36: Reduced Sleep-2.3 ± 1.81
Week 40: Reduced Sleep-2.3 ± 1.76
Week 44: Reduced Sleep-2.4 ± 1.61
Week 48: Reduced Sleep-2.3 ± 1.69
Week 52: Reduced Sleep-2.2 ± 1.64
Week 56: Reduced Sleep-2.2 ± 1.73
Week 60: Reduced Sleep-2.3 ± 1.62
Week 64: Reduced Sleep-2.2 ± 1.70
Week 68: Reduced Sleep-2.4 ± 1.82
Week 72: Reduced Sleep-2.3 ± 1.66
Week 76: Reduced Sleep-2.4 ± 1.67
Week 80: Reduced Sleep-2.3 ± 1.84
Week 84: Reduced Sleep-2.4 ± 1.73
Week 88: Reduced Sleep-2.5 ± 1.58
Week 92: Reduced Sleep-2.4 ± 1.70
Week 96: Reduced Sleep-2.5 ± 1.66
Week 100: Reduced Sleep-2.5 ± 1.66
Week 104: Reduced Sleep-2.6 ± 1.76
Week 4: Reduced Appetite-1.7 ± 1.78
Week 8: Reduced Appetite-1.7 ± 1.75
Week 12: Reduced Appetite-1.9 ± 1.68
Week 16: Reduced Appetite-2.0 ± 1.69
Week 20: Reduced Appetite-1.8 ± 1.74
Week 24: Reduced Appetite-1.9 ± 1.74
Week 28: Reduced Appetite-1.9 ± 1.74
Week 32: Reduced Appetite-1.9 ± 1.72
Week 36: Reduced Appetite-1.9 ± 1.81
Week 40: Reduced Appetite-1.9 ± 1.69
Week 44: Reduced Appetite-1.9 ± 1.81
Week 48: Reduced Appetite-1.9 ± 1.73
Week 52: Reduced Appetite-1.9 ± 1.78
Week 56: Reduced Appetite-1.9 ± 1.65
Week 60: Reduced Appetite-1.9 ± 1.68
Week 64: Reduced Appetite-2.0 ± 1.67
Week 68: Reduced Appetite-2.0 ± 1.69
Week 72: Reduced Appetite-2.0 ± 1.64
Week 76: Reduced Appetite-2.0 ± 1.62
Week 80: Reduced Appetite-1.9 ± 1.78
Week 84: Reduced Appetite-2.0 ± 1.70
Week 88: Reduced Appetite-2.0 ± 1.73
Week 92: Reduced Appetite-2.0 ± 1.67
Week 96: Reduced Appetite-2.1 ± 1.61
Week 100: Reduced Appetite-2.0 ± 1.69
Week 104: Reduced Appetite-2.1 ± 1.72
Week 4: Concentration Difficulties-2.2 ± 1.28
Week 8: Concentration Difficulties-2.3 ± 1.37
Week 12: Concentration Difficulties-2.3 ± 1.26
Week 16: Concentration Difficulties-2.3 ± 1.28
Week 20: Concentration Difficulties-2.2 ± 1.25
Week 24: Concentration Difficulties-2.3 ± 1.26
Week 28: Concentration Difficulties-2.2 ± 1.28
Week 32: Concentration Difficulties-2.2 ± 1.23
Week 36: Concentration Difficulties-2.3 ± 1.28
Week 40: Concentration Difficulties-2.3 ± 1.21
Week 44: Concentration Difficulties-2.3 ± 1.26
Week 48: Concentration Difficulties-2.4 ± 1.18
Week 52: Concentration Difficulties-2.4 ± 1.20
Week 56: Concentration Difficulties-2.4 ± 1.14
Week 60: Concentration Difficulties-2.3 ± 1.19
Week 64: Concentration Difficulties-2.4 ± 1.25
Week 68: Concentration Difficulties-2.4 ± 1.26
Week 72: Concentration Difficulties-2.4 ± 1.10
Week 76: Concentration Difficulties-2.5 ± 1.17
Week 80: Concentration Difficulties-2.4 ± 1.10
Week 84: Concentration Difficulties-2.4 ± 1.14
Week 88: Concentration Difficulties-2.6 ± 1.08
Week 92: Concentration Difficulties-2.6 ± 1.12
Week 96: Concentration Difficulties-2.5 ± 1.10
Week 100: Concentration Difficulties-2.6 ± 1.06
Week 104: Concentration Difficulties-2.6 ± 1.10
Week 4: Lassitude-2.5 ± 1.36
Week 8: Lassitude-2.4 ± 1.33
Week 12: Lassitude-2.5 ± 1.22
Week 16: Lassitude-2.5 ± 1.27
Week 20: Lassitude-2.6 ± 1.33
Week 24: Lassitude-2.6 ± 1.21
Week 28: Lassitude-2.6 ± 1.21
Week 32: Lassitude-2.5 ± 1.20
Week 36: Lassitude-2.6 ± 1.30
Week 40: Lassitude-2.5 ± 1.17
Week 44: Lassitude-2.6 ± 1.16
Week 48: Lassitude-2.6 ± 1.19
Week 52: Lassitude-2.6 ± 1.15
Week 56: Lassitude-2.6 ± 1.16
Week 60: Lassitude-2.6 ± 1.25
Week 64: Lassitude-2.6 ± 1.25
Week 68: Lassitude-2.6 ± 1.21
Week 72: Lassitude-2.7 ± 1.13
Week 76: Lassitude-2.6 ± 1.11
Week 80: Lassitude-2.8 ± 1.00
Week 84: Lassitude-2.6 ± 1.09
Week 88: Lassitude-2.8 ± 1.14
Week 92: Lassitude-2.7 ± 1.09
Week 96: Lassitude-2.8 ± 1.11
Week 100: Lassitude-2.9 ± 1.00
Week 104: Lassitude-2.9 ± 0.91
Week 4: Inability to Feel-2.7 ± 1.29
Week 8: Inability to Feel-2.6 ± 1.34
Week 12: Inability to Feel-2.7 ± 1.24
Week 16: Inability to Feel-2.8 ± 1.20
Week 20: Inability to Feel-2.6 ± 1.19
Week 24: Inability to Feel-2.8 ± 1.24
Week 28: Inability to Feel-2.7 ± 1.27
Week 32: Inability to Feel-2.8 ± 1.30
Week 36: Inability to Feel-2.8 ± 1.28
Week 40: Inability to Feel-2.8 ± 1.22
Week 44: Inability to Feel-2.8 ± 1.26
Week 48: Inability to Feel-2.7 ± 1.27
Week 52: Inability to Feel-2.7 ± 1.26
Week 56: Inability to Feel-2.8 ± 1.22
Week 60: Inability to Feel-2.9 ± 1.20
Week 64: Inability to Feel-2.9 ± 1.21
Week 68: Inability to Feel-2.8 ± 1.14
Week 72: Inability to Feel-2.8 ± 1.24
Week 76: Inability to Feel-2.8 ± 1.20
Week 80: Inability to Feel-2.9 ± 1.29
Week 84: Inability to Feel-2.9 ± 1.34
Week 88: Inability to Feel-2.9 ± 1.13
Week 92: Inability to Feel-3.0 ± 1.20
Week 96: Inability to Feel-3.0 ± 1.13
Week 100: Inability to Feel-3.0 ± 1.15
Week 104: Inability to Feel-3.0 ± 1.23
Week 4: Pessimistic Thoughts-2.0 ± 1.25
Week 8: Pessimistic Thoughts-2.0 ± 1.24
Week 12: Pessimistic Thoughts-2.1 ± 1.26
Week 16: Pessimistic Thoughts-2.1 ± 1.26
Week 20: Pessimistic Thoughts-2.0 ± 1.25
Week 24: Pessimistic Thoughts-2.1 ± 1.24
Week 28: Pessimistic Thoughts-2.1 ± 1.20
Week 32: Pessimistic Thoughts-2.1 ± 1.23
Week 36: Pessimistic Thoughts-2.0 ± 1.33
Week 40: Pessimistic Thoughts-2.1 ± 1.27
Week 44: Pessimistic Thoughts-2.1 ± 1.23
Week 48: Pessimistic Thoughts-2.1 ± 1.24
Week 52: Pessimistic Thoughts-2.0 ± 1.22
Week 56: Pessimistic Thoughts-2.0 ± 1.25
Week 60: Pessimistic Thoughts-2.1 ± 1.27
Week 64: Pessimistic Thoughts-2.1 ± 1.26
Week 68: Pessimistic Thoughts-2.1 ± 1.21
Week 72: Pessimistic Thoughts-2.1 ± 1.17
Week 76: Pessimistic Thoughts-2.1 ± 1.16
Week 80: Pessimistic Thoughts-2.1 ± 1.23
Week 84: Pessimistic Thoughts-2.1 ± 1.20
Week 88: Pessimistic Thoughts-2.1 ± 1.18
Week 92: Pessimistic Thoughts-2.1 ± 1.21
Week 96: Pessimistic Thoughts-2.2 ± 1.16
Week 100: Pessimistic Thoughts-2.2 ± 1.22
Week 104: Pessimistic Thoughts-2.2 ± 1.18
Week 4: Suicidal Thoughts-0.8 ± 1.05
Week 8: Suicidal Thoughts-0.7 ± 0.97
Week 12: Suicidal Thoughts-0.8 ± 1.05
Week 16: Suicidal Thoughts-0.8 ± 1.04
Week 20: Suicidal Thoughts-0.8 ± 1.01
Week 24: Suicidal Thoughts-0.8 ± 1.06
Week 28: Suicidal Thoughts-0.8 ± 1.02
Week 32: Suicidal Thoughts-0.8 ± 1.01
Week 36: Suicidal Thoughts-0.7 ± 1.13
Week 40: Suicidal Thoughts-0.8 ± 0.97
Week 44: Suicidal Thoughts-0.7 ± 0.91
Week 48: Suicidal Thoughts-0.8 ± 0.98
Week 52: Suicidal Thoughts-0.8 ± 0.98
Week 56: Suicidal Thoughts-0.8 ± 0.99
Week 60: Suicidal Thoughts-0.8 ± 0.97
Week 64: Suicidal Thoughts-0.8 ± 0.98
Week 68: Suicidal Thoughts-0.8 ± 0.98
Week 72: Suicidal Thoughts-0.8 ± 1.01
Week 76: Suicidal Thoughts-0.8 ± 1.01
Week 80: Suicidal Thoughts-0.8 ± 1.03
Week 84: Suicidal Thoughts-0.8 ± 0.97
Week 88: Suicidal Thoughts-0.8 ± 0.98
Week 92: Suicidal Thoughts-0.8 ± 0.97
Week 96: Suicidal Thoughts-0.8 ± 1.04
Week 100: Suicidal Thoughts-0.8 ± 1.03
Week 104: Suicidal Thoughts-0.8 ± 1.01
SecondaryChange From Baseline of Study 54135419TRD3013 in Clinical Global Impression -Severity (CGI-S) Scale Score

Change from Baseline of Study 54135419TRD3013 in CGI-S scale score were reported. The CGI-S provided an overall clinician-determined summary measure of the severity of the participant's illness that took into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluated the severity of psychopathology on a scale of 1 to 7: where, 1 = normal (not ill); 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participant's. Negative change in score indicated improvement. Participant's with a score of zero were considered missing.

Time frame:
Baseline (Day 1 of study 54135419TRD3013) up to weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, and 104 of study 54135419TRD4010
Reported as:
Mean · score on a scale
Change From Baseline of Study 54135419TRD3013 in Clinical Global Impression -Severity (CGI-S) Scale Score
score on a scaleEsketamine Nasal Spray + Oral Antidepressant (AD)
Week 4-2.5 ± 1.00
Week 8-2.6 ± 1.02
Week 12-2.6 ± 0.99
Week 16-2.6 ± 0.96
Week 20-2.6 ± 0.96
Week 24-2.7 ± 0.96
Week 28-2.8 ± 0.96
Week 32-2.7 ± 1.01
Week 36-2.7 ± 0.99
Week 40-2.9 ± 0.99
Week 44-2.9 ± 0.98
Week 48-2.9 ± 0.96
Week 52-2.8 ± 1.00
Week 56-2.9 ± 0.93
Week 60-2.9 ± 0.96
Week 64-2.9 ± 0.99
Week 68-2.9 ± 0.93
Week 72-2.9 ± 0.93
Week 76-2.9 ± 0.93
Week 80-2.9 ± 0.91
Week 84-3.0 ± 0.86
Week 88-3.0 ± 0.88
Week 92-3.0 ± 0.88
Week 96-3.1 ± 0.88
Week 100-3.1 ± 0.87
Week 104-3.1 ± 0.85
SecondaryChange From Baseline of Study 54135419TRD3013 in Patient Health Questionnaire (PHQ) 9-item Total Score

Change from Baseline of Study 54135419TRD3013 in PHQ 9-item total score were reported. The PHQ-9 was a validated 9-item, patient-reported outcome (PRO) measure to assess depressive symptoms. Each item was rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses were summed to a total score with a range of 0 to 27. Higher scores indicated greater severity of depressive symptoms.

Time frame:
Baseline (Day 1 of study 54135419TRD3013) up to weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, and 104 of study 54135419TRD4010
Reported as:
Mean · score on a scale
Change From Baseline of Study 54135419TRD3013 in Patient Health Questionnaire (PHQ) 9-item Total Score
score on a scaleEsketamine Nasal Spray + Oral Antidepressant (AD)
Week 4-11.0 ± 5.80
Week 8-10.9 ± 5.98
Week 12-10.9 ± 5.73
Week 16-11.2 ± 5.53
Week 20-11.3 ± 5.46
Week 24-11.3 ± 5.19
Week 28-11.5 ± 5.25
Week 32-11.3 ± 5.71
Week 36-11.6 ± 6.06
Week 40-11.5 ± 5.55
Week 44-11.9 ± 5.67
Week 48-11.9 ± 5.61
Week 52-11.4 ± 5.55
Week 56-12.0 ± 5.19
Week 60-11.9 ± 5.24
Week 64-11.9 ± 5.18
Week 68-11.9 ± 5.60
Week 72-12.1 ± 5.00
Week 76-12.2 ± 5.12
Week 80-12.1 ± 5.28
Week 84-11.9 ± 5.19
Week 88-12.2 ± 5.21
Week 92-12.5 ± 5.11
Week 96-12.2 ± 5.10
Week 100-12.7 ± 4.78
Week 104-12.7 ± 4.97
SecondaryChange From Baseline of Study 54135419TRD3013 in European Quality of Life (EuroQol) 5 Dimension 5-Level (EQ-5D-5L): Health Status Index

Change from baseline of Study 54135419TRD3013 in EQ-5D-5LQuestionnaire Score: health status index were reported. The EQ-5D-5L descriptive system comprised the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions were divided into 5 levels of perceived problems (level 1 = no problem, level 2 = slight problems, level 3 = moderate problems, level 4 = severe problems, level 5 = extreme problems). The participant selected an answer for each of the 5 dimensions considering a response that best matched participant's health "today." Responses were used to generate health status index ranged from -0.594 to 1 (where 1 represents full health and negative values represent health states considered worse than dead). Positive change in score indicated improvement.

Time frame:
Baseline (Day 1 of Study 54135419TRD3013) up to weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, and 104 of study 54135419TRD4010
Reported as:
Mean · score on a scale
Change From Baseline of Study 54135419TRD3013 in European Quality of Life (EuroQol) 5 Dimension 5-Level (EQ-5D-5L): Health Status Index
score on a scaleEsketamine Nasal Spray + Oral Antidepressant (AD)
Week 40.323 ± 0.2479
Week 80.320 ± 0.2518
Week 120.325 ± 0.2379
Week 160.322 ± 0.2568
Week 200.336 ± 0.2444
Week 240.331 ± 0.2337
Week 280.323 ± 0.2415
Week 320.335 ± 0.2377
Week 360.341 ± 0.2512
Week 400.333 ± 0.2364
Week 440.343 ± 0.2576
Week 480.345 ± 0.2317
Week 520.332 ± 0.2374
Week 560.348 ± 0.2348
Week 600.364 ± 0.2322
Week 640.350 ± 0.2422
Week 680.337 ± 0.2546
Week 720.354 ± 0.2295
Week 760.357 ± 0.2440
Week 800.362 ± 0.2375
Week 840.350 ± 0.2295
Week 880.366 ± 0.2385
Week 920.367 ± 0.2275
Week 960.375 ± 0.2333
Week 1000.387 ± 0.2321
Week 1040.387 ± 0.2444
SecondaryChange From Baseline of Study 54135419TRD3013 in European Quality of Life (EuroQol) 5 Dimension 5-Level (EQ-5D-5L): Visual Analogue Scale (VAS)

Change from baseline of Study 54135419TRD3013 in EQ-5D-5L: visual analogue scale were reported. EQ-VAS self-rating recorded the participant's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Positive change in score indicated improvement.

Time frame:
Baseline (Day 1 of Study 54135419TRD3013) up to weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, and 104 of study 54135419TRD4010
Reported as:
Mean · score on a scale
Change From Baseline of Study 54135419TRD3013 in European Quality of Life (EuroQol) 5 Dimension 5-Level (EQ-5D-5L): Visual Analogue Scale (VAS)
score on a scaleEsketamine Nasal Spray + Oral Antidepressant (AD)
Week 427.35 ± 20.595
Week 826.24 ± 21.939
Week 1226.74 ± 20.884
Week 1627.98 ± 20.523
Week 2027.85 ± 20.143
Week 2428.83 ± 20.438
Week 2828.23 ± 21.006
Week 3228.30 ± 21.119
Week 3629.99 ± 19.901
Week 4028.56 ± 21.210
Week 4429.19 ± 21.259
Week 4829.57 ± 21.717
Week 5229.60 ± 21.419
Week 5629.90 ± 20.828
Week 6030.47 ± 20.423
Week 6430.49 ± 20.352
Week 6829.82 ± 20.195
Week 7230.84 ± 20.252
Week 7631.90 ± 19.866
Week 8031.23 ± 20.512
Week 8430.40 ± 19.697
Week 8831.10 ± 20.469
Week 9231.87 ± 20.228
Week 9630.75 ± 19.759
Week 10031.66 ± 18.887
Week 10433.75 ± 19.356

Adverse events

Collected over From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Esketamine + Oral AD1/183 (0.5%)11/183 (6%)145/183 (79.2%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventEsketamine + Oral AD
Acute coronary syndromeCardiac disorders1/183
GoitreEndocrine disorders1/183
Macular holeEye disorders1/183
Alcohol poisoningInjury, poisoning and procedural complications1/183
Multiple injuriesInjury, poisoning and procedural complications1/183
Back painMusculoskeletal and connective tissue disorders1/183
Brain neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/183
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/183
Psychomotor hyperactivityNervous system disorders1/183
DepressionPsychiatric disorders1/183
Most frequent other events
Showing 10 of 21
Most frequent other events
EventEsketamine + Oral AD
HeadacheNervous system disorders81/183
DizzinessNervous system disorders50/183
NauseaGastrointestinal disorders37/183
NasopharyngitisInfections and infestations37/183
VertigoEar and labyrinth disorders32/183
COVID-19Infections and infestations30/183
SomnolenceNervous system disorders24/183
Back painMusculoskeletal and connective tissue disorders20/183
DissociationPsychiatric disorders19/183
Abdominal painGastrointestinal disorders15/183

Baseline characteristics

Age, Continuous
Age, Continuous(years)Esketamine Nasal Spray + Oral Antidepressant (AD)
Mean44.6 ± 13.07
Age, Customized
Age, Customized(Participants)Esketamine Nasal Spray + Oral Antidepressant (AD)
18-64 years174
>=65 years9
Sex: Female, Male
Sex: Female, Male(Participants)Esketamine Nasal Spray + Oral Antidepressant (AD)
Female128
Male55
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Esketamine Nasal Spray + Oral Antidepressant (AD)
Hispanic or Latino12
Not Hispanic or Latino60
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Esketamine Nasal Spray + Oral Antidepressant (AD)
American Indian or Alaska Native0
Asian6
Native Hawaiian or Other Pacific Islander66
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Body mass index
Body mass index(Participants)Esketamine Nasal Spray + Oral Antidepressant (AD)
Underweight <18.5 kg/m^25
Normal 18.5 to <25 kg/m^263
Overweight 25 to <30 kg/m^246
Obese >=30 kg/m^241
08

Study locations

59 sites
  • FunDaMos
    Buenos Aires, C1405BOA, Argentina
  • CEN Consultorios Especializados en Neurociencias
    Córdoba, 5000FJF, Argentina
  • Fundacion Lennox
    Córdoba, 5000, Argentina
  • Instituto Medico DAMIC
    Córdoba, X5003DCE, Argentina
  • Sanatorio Prof Leon S Morra S A
    Córdoba, X5009BIN, Argentina
  • Instituto de Neurociencias San Agustin
    La Plata, 1900, Argentina
  • C I A P Centro de investigacion y Asistencia en Psiquiatria
    Rosario, 2000, Argentina
  • Anima
    Alken, 3570, Belgium
  • Mental Health Center - Rousse
    Rousse, 7003, Bulgaria
  • Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sveti Naum
    Sofia, 1113, Bulgaria
  • Centre for Mental Health Prof.N.Shipkovenski EOOD
    Sofia, 1377, Bulgaria
  • Psychiatricka ambulance Saint Anne s.r.o.
    Brno, 60200, Czechia
  • Psychiatricka ambulance, MUDr. Marta Holanova
    Brno, 61500, Czechia
  • NeuropsychiatrieHK, s.r.o.
    Hradec Králové, 50002, Czechia
  • A Shine S R O
    Pilsen, 31200, Czechia
  • AD71 s.r.o.
    Prague, 109 00, Czechia
  • Medical Services Prague S R O
    Prague, 16000, Czechia
  • Institut Neuropsychiatricke pece
    Prague, 18600, Czechia
  • Mederon LTD at ARTES
    Helsinki, 00270, Finland
  • Medizinisches Versorgungszentrum LiO GmbH
    Berlin, 12209, Germany
  • Praxis Dr. med. Kirsten Hahn
    Berlin, 13187, Germany
  • Klinikum Dortmund gGmbH
    Dortmund, 44287, Germany
  • Universitätsklinikum Freiburg - Abteilung für Psychiatrie u. Psychotherapie mit Poliklinik
    Freiburg im Breisgau, 79104, Germany
  • Klinische Forschung Hamburg
    Hamburg, 20253, Germany
  • Oberhavel Kliniken GmbH
    Hennigsdorf, 16761, Germany
  • Pharmakologisches Studienzentrum Chemnitz GmbH
    Mittweida, 09111, Germany
  • Danuvius Klinik Pfaffenhofen Fachklinik für Psychiatrie, Psychotherapie und Psychosomatik
    Pfaffenhofen, 85276, Germany
  • Somni Bene GmbH
    Schwerin, 19053, Germany
  • Klinische Forschung Schwerin GmbH
    Schwerin, 19055, Germany
  • Psychiatric Clinic 'Agios Charalampos'
    Heraklion, 71305, Greece
  • University General Hospital of Rio Patras
    Pátrai, 26504, Greece
  • G Papanikolaou Hospital of Thessaloniki
    Thessaloniki, 57010, Greece
  • Processus Kft
    Budapest, 1137, Hungary
  • Bugat Pal Korhaz
    Gyöngyös, 3200, Hungary
  • Petz Aladar Megyei Oktato Korhaz
    Győr, H-9024, Hungary
  • Hospital Raja Permaisuri Bainun
    Ipoh, 30990, Malaysia
  • University Malaya Medical Centre
    Kuala Lumpur, 59100, Malaysia
  • Hospital Pengajar Universiti Putra Malaysia
    Serdang, 43400, Malaysia
  • Hospital Tuanku Jaafar
    Seremban, 70300, Malaysia
  • Mlynowamed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk
    Bialystok, 15-404, Poland
  • Osrodek Badan Klinicznych CLINSANTE S C
    Bydgoszcz, 85 794, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80 214, Poland
  • Centrum Badan Klinicznych PI House sp z o o
    Gdansk, 80 546, Poland
  • Centrum Medyczne Care Clinic Katowice
    Katowice, 40-568, Poland
  • Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS
    Leszno, 64-100, Poland
  • Specjalistyczny Psychiatryczny Zespol Opieki Zdrowotnej w Lodzi Szpital im. J. Babinskiego
    Lodz, 91-229, Poland
  • SPZOZ CSK UM w Lodzi Klinika Zaburzen Afektywnych i Psychotycznych
    Lodz, 92-216, Poland
  • Osrodek Badan Klinicznych CLINSANTE S C
    Torun, 87 100, Poland
  • Cape Town Clinical Research Centre
    Cape Town, 7530, South Africa
  • Gert Bosch Pretoria South Africa
    Pretoria, 0 042, South Africa
  • Severance Hospital Yonsei University Health System
    Seoul, 03722, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Changhua Christian Hospital
    Changhua, 500, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Chang Gung Memorial Hospital
    Taoyuan, 333, Taiwan
  • Hacettepe University Medical Faculty
    Ankara, 6100, Turkey (Türkiye)
  • Erenkoy Mental Health Hospital
    Istanbul, 34736, Turkey (Türkiye)
  • Liv Hospital
    Samsun, 55020, Turkey (Türkiye)
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Jul 2024, 38 months.

Results were first posted in Sep 2025, 1 year 1 month after primary completion.

Of 98 phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's 38 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2021
First posted
Apr 2, 2021
StartActual
Apr 26, 2021
Primary completionActual
Jul 22, 2024
CompletionActual
Jul 22, 2024
Results first posted
Sep 18, 2025
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04829318
Lead sponsor
Janssen-Cilag Ltd.
Responsible party
Sponsor
First posted
Apr 2, 2021
Start date
Apr 26, 2021
Primary completion
Jul 22, 2024
Completion
Jul 22, 2024
Results posted
Sep 18, 2025
Last update
Sep 18, 2025

Study contacts

Janssen-Cilag Ltd. Clinical Trial
study director · Janssen-Cilag Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion